Company news

OBI Pharma, Inc. news in 2022

OBI Pharma, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Announcement on behalf of AP Biosciences to file application for Phase I human clinical trial of Bispecific Antibody, AP203, to US FDA

August 12, 2022

Announcement of amendment of the Company's 2021 Annual Report

August 11, 2022

Announcement that the cumulative reduction of shareholding in major subsidiary, AP Biosciences, has reached more than 10%

August 8, 2022

Announcement on behalf of AP Biosciences that preemptive rights forfeited by directors are over 50% and made available to specific persons

August 8, 2022

The Company’s BOD resolved to forfeit the subscription of AP Biosciences’ cash capital increase and distribute the rights to its shareholders

August 8, 2022

OBI Pharma forfeits subscription of AP Biosciences’ cash capital increase, distributes rights to its shareholders and sets target date

August 8, 2022

Decks in 2022